摘要
Objectives： To investigate the effect of Shenfu Injection（参附注射液, SFI） on inflammatory factors in patients with acute myocardial infarction complicated by cardiogenic shock（CS） treated with and intra-aortic balloon pump（IABP）. Methods： This study enrolled 60 patients with ST-segment elevation myocardial infarction（STEMI） complicated by CS. Patients underwent IABP and emergency percutaneous coronary intervention（PCI） were randomly divided into two groups by random number table with 30 cases in each group, one given SFI treatment（100 m L/24 h）, one not. The two groups were then compared in a clinical setting for left ventricular function, biochemical indicators and Inflammatory factors, including C-reactive proteins（CRP）, interleukin-1（IL-1） and tumor necrosis factor alpha（TNF-α）. Major adverse cardiac and cerebrovascular events（MACCE） events were compared between patients of the two groups both in-hospital and in follow-ups. Results： The IABP support treatment times of patients in the IABP＋SFI group were significantly shorter than the IABP group（52.87±28.84 vs. 87.45±87.31, P=0.047）. In the patients of the IABP＋SFI group, the CRP peak appeared in 24 h after PCI operation. The CRP peak in the patients of the IABP＋SFI group was significantly lower than that in the IABP group（31.27±3.93 vs. 34.62±3.47, P=0.001）. The increases in range of TNF-α in the patients of the IABP＋SFI group were significantly lower than those of the IABP group（182.29±22.79 vs. 195.54±12.02, P=0.007）. The increases in range of IL-1 in the patients of the IABP＋SFI group were significantly lower than those of the IABP group（214.98±29.22 vs. 228.60±7.03, P=0.019）. The amplitude elevated TNF-α 72 h after admission was an independent risk factor of in-hospital MACCE events（OR 0.973, 95% CI 0.890–0.987, P=0.014） in patients with STEMI and CS. Conclusion： Patients with STEMI complicated by CS treated by IABP and SFI had a reduced inflammatory reaction, a reduced dependence of CS on IABP and shortened the course of disease.
Objectives： To investigate the effect of Shenfu Injection（参附注射液, SFI） on inflammatory factors in patients with acute myocardial infarction complicated by cardiogenic shock（CS） treated with and intra-aortic balloon pump（IABP）. Methods： This study enrolled 60 patients with ST-segment elevation myocardial infarction（STEMI） complicated by CS. Patients underwent IABP and emergency percutaneous coronary intervention（PCI） were randomly divided into two groups by random number table with 30 cases in each group, one given SFI treatment（100 m L/24 h）, one not. The two groups were then compared in a clinical setting for left ventricular function, biochemical indicators and Inflammatory factors, including C-reactive proteins（CRP）, interleukin-1（IL-1） and tumor necrosis factor alpha（TNF-α）. Major adverse cardiac and cerebrovascular events（MACCE） events were compared between patients of the two groups both in-hospital and in follow-ups. Results： The IABP support treatment times of patients in the IABP＋SFI group were significantly shorter than the IABP group（52.87±28.84 vs. 87.45±87.31, P=0.047）. In the patients of the IABP＋SFI group, the CRP peak appeared in 24 h after PCI operation. The CRP peak in the patients of the IABP＋SFI group was significantly lower than that in the IABP group（31.27±3.93 vs. 34.62±3.47, P=0.001）. The increases in range of TNF-α in the patients of the IABP＋SFI group were significantly lower than those of the IABP group（182.29±22.79 vs. 195.54±12.02, P=0.007）. The increases in range of IL-1 in the patients of the IABP＋SFI group were significantly lower than those of the IABP group（214.98±29.22 vs. 228.60±7.03, P=0.019）. The amplitude elevated TNF-α 72 h after admission was an independent risk factor of in-hospital MACCE events（OR 0.973, 95% CI 0.890–0.987, P=0.014） in patients with STEMI and CS. Conclusion： Patients with STEMI complicated by CS treated by IABP and SFI had a reduced inflammatory reaction, a reduced dependence of CS on IABP and shortened the course of disease.
基金
Supported by Beijing Chinese Medicine Technology Development Surfaces Subject of Special Funds(No.JJ2013-19)
